Trial Profile
Cetuximab Monotherapy or Cetuximab + Chemotherapy for Third Line Rechallenge in Metastatic Colorectal Cancer, RAS+ (RAt Sarcoma Gene) Wild Type Patients, Who Were Treated With Cetuximab Chemotherapy as First Line Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 02 Aug 2022 Status changed from recruiting to discontinued.
- 17 May 2018 New trial record